Open Access

Thymosin β4 and β10 in Sjögren’s syndrome: saliva proteomics and minor salivary glands expression

  • Silvia Bosello1,
  • Giusy Peluso1,
  • Federica Iavarone2,
  • Barbara Tolusso1,
  • Irene Messana3,
  • Gavino Faa4,
  • Massimo Castagnola2 and
  • Gianfranco Ferraccioli1, 5Email author
Contributed equally
Arthritis Research & Therapy201618:229

https://doi.org/10.1186/s13075-016-1134-7

Received: 19 January 2016

Accepted: 20 September 2016

Published: 6 October 2016

Abstract

Background

In the present study, we investigated whether thymosin β (Tβ) in saliva and in minor salivary glands is differentially expressed in patients with primary Sjögren’s syndrome (pSS) and patients with autoimmune diseases (systemic sclerosis [SSc], systemic lupus erythematosus [SLE], and rheumatoid arthritis [RA], with and without sicca syndrome [ss]).

Methods

Saliva specimens of nine patients with pSS, seven with ss/SSc, seven with ss/SLE, seven with ss/RA, seven with SSc, seven with SLE, and seven with RA, as well as ten healthy subjects, were analyzed using a high-performance liquid chromatograph coupled with a mass spectrometer equipped with an electrospray ionization source to investigate the presence and levels of Tβ4, Tβ4 sulfoxide, and Tβ10. Immunostaining for Tβ4 and Tβ10 was performed on minor salivary glands of patients with pSS and ss.

Results

4 levels were statistically higher in patients with pSS with respect to the other subgroups. Tβ10 was detectable in 66.7 % of patients with pSS and in 42.8 % of those with ss/SSc, while Tβ4 sulfoxide was detectable in 44.4 % of patients with pSS and in 42.9 % of those with ss/SSc. Tβ10 and Tβ4 sulfoxide were not detectable in patients without associated ss and in healthy control subjects. Regarding thymosin immunostaining, all patients had immunoreactivity for Tβ10, and a comparable distribution pattern in the four different subgroups of patients was observed. Tβ4 immunoreactivity was present in patients with ss/SSc and those with ss/SLE, while it was completely absent in patients with pSS and those with ss/RA.

Conclusions

Our data show that higher salivary Tβ expression characterizes patients with pSS, while Tβ4 sulfoxide and Tβ10 salivary expression was selectively present in patients with sicca symptoms. Moreover, at the immunohistochemical level in patients with pSS, minor salivary glands showed a peculiar pattern characterized by immunostaining for Tβ10 in acinar cells in the absence of any reactivity for Tβ4. These findings, taken together, suggest a different role for Tβ4 and Tβ10 in patients with pSS who have ss and other autoimmune disease.

Keywords

Thymosin β4 Thymosin β10 Sjögren’s syndrome Saliva Proteomics Immunohistochemistry Minor salivary glands

Background

Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, including salivary and lachrymal glands, leading to qualitatively altered and diminished or absent glandular secretion. pSS is also characterized by marked B-lymphocyte hyperreactivity supported by hypergammaglobulinemia associated with the increase of a variety of serum autoantibodies [1]. The characteristic involvement of salivary and lachrymal glands, clinically evidenced by dry mouth (xerostomia) and/or dry eyes (xerophthalmia), makes pSS an interesting application field for salivary proteomic analysis. Saliva and tears are easy and noninvasive biological fluids to collect and can mirror local and systemic pathological changes of the disease [24]. In previous studies on the salivary proteome in patients with pSS, researchers identified a number of proteins as possible pSS biomarkers. Some of these biomarkers showed significantly different levels from those of healthy subjects, whereas other biomarkers were detected exclusively in the saliva of patients with pSS [36]. In general, proteins of acinar origin were reduced in patients with pSS, whereas acute inflammatory phase proteins were increased in subjects with pSS, compared with those of healthy subjects.

Recently, β-thymosins (Tβs), a versatile family of small peptides with interesting intra- and extracellular activities that include cardiac protection, angiogenesis, stimulation of wound healing, and hair growth [716], was identified in human saliva and in tears [17, 18]. Tβs play pivotal roles in the cell cytoskeletal system, acting as G-actin-sequestering molecules, suggesting that their release by damaged cells might play a role in tissue repair, such as in damaged cornea [19]. In particular, Tβ4, the most abundant Tβ in human tissues [7, 8], plays an important role in suppressing the production of interleukin-8 following stimulation by tumor necrosis factor-α, acting as an antimicrobial, anti-inflammatory, and antiapoptotic factor on gingival fibroblasts [20]. Moreover, our group recently reported that Tβs are probably involved in the development of the oral cavity and its annexes [21]. Another member of the Tβ family, Tβ10, is usually detectable at concentrations about five- to tenfold lower than Tβ4 in human tissues, but it has been reported to be overexpressed in human carcinogenesis [22] and in fetal tissues, including the developing human brain [23]. Involvement of Tβ10 in the development of the oral cavity, and in particular tooth germ development and tooth root formation, was reported recently in a mice study [24]. In addition, our group reported strong expression of Tβ10 in the human salivary glands during development [21]. Tβ4 sulfoxide was reported to have anti-inflammatory properties [25], being overexpressed in the presence of oxidative stress, due to its potential scavenger properties [26].

Because, to the best of our knowledge, no data had previously been reported on the presence of Tβ4, Tβ4 sulfoxide, and Tβ10 in human saliva of patients with Sjögren’s syndrome (SS), the aim of this study was to investigate the presence and levels of salivary Tβs and the immunoreactivity of these peptides in minor salivary glands in a cohort of patients with SS and in patients with other autoimmune diseases, with and without sicca syndrome (ss), to better understand the possible role of these peptides in patients with pSS as well as patients with ss and other autoimmune diseases.

Methods

Patients and control subjects

All female patients were enrolled at the rheumatology clinic at the Catholic University of Rome, and the study was approved by the Catholic University Ethics Committee in Rome. After we obtained signed informed consent, we collected saliva specimens from nine patients with pSS according to previous and revised criteria for the disease [27, 28]. Patients with pSS had a mean age of 63.0 ± 11.2 years and a mean disease duration of 12.0 ± 7.1 years (Table 1).
Table 1

Demographic and clinical characteristics of the patients and healthy control subjects enrolled in the study

 

pSS (n = 9)

ss/SSc (n = 7)

ss/SLE (n = 7)

ss/RA (n = 7)

SSc (n = 7)

SLE (n = 7)

RA (n = 7)

HC (n = 10)

Age, years, mean ± SD

55.8 ± 13

63 ± 11

51 ± 16

61 ± 8

60.2 ± 7

48. ± 10

64.1. ± 9

56.6 ± 12.5

Disease duration, years, mean ± SD

7.9 ± 4.2

12 ± 7

12 ± 9

10 ± 7

10.4 ± 8

11 ± 8

9.4 ± 8

N/A

Anti-Ro/SSA- and/or anti-La/SSB-positive, n

9

0

0

0

0

0

0

0

ANA-positive, n

6

7

7

1

7

7

2

0

RF-positive, n

5

0

0

6

0

0

4

0

Focus score ≥1, n

6

0

0

0

N/A

N/A

N/A

0

UWS <1.5 ml/15 minutes, n

9

7

7

7

0

0

0

0

Schirmer test result <5 mm/5 minutes, n

9

7

7

7

0

0

0

0

Xerostomia, n

9

7

7

7

0

0

0

0

Xerophthalmia, n

9

7

7

7

0

0

0

0

Abbreviation: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy control subjects, UWS Unstimulated whole saliva, ANA Antinuclear antibodies, RF Rheumatoid factor, N/A Not applicable

As control subjects, we considered three age-matched groups:
  1. 1.

    Ten healthy subjects who had no signs or symptoms of ss and who were antinuclear autoantibody-negative, anti-extractable nuclear antigen autoantibody-negative, and rheumatoid factor autoantibody-negative

     
  2. 2.

    Twenty-one patients with ss associated with systemic sclerosis (SSc) (seven patients), with systemic lupus erythematosus (SLE) (seven patients), and with rheumatoid arthritis (RA) (seven patients); all of these patients complained of xerostomia and xerophthalmia, had a Schirmer test result <5 mm in 5 minutes, and had unstimulated whole saliva flow <1.5 ml in 15 minutes [27], and none of them had anti-Ro/SSA or anti-La/SSB autoantibodies and lymphocytic infiltration of the salivary glands

     
  3. 3.

    Seven patients with SSc, seven with SLE, and seven with RA without symptoms or signs of ss

     

All patients were diagnosed according to the revised international classification criteria for SSc, SLE, and RA [2931]. The disease durations were comparable in the different patient study groups (Table 1).

In patients with pSS and with ss associated with SSc, SLE, or RA, saliva specimens were also collected after 30 minutes, 60 minutes, and 24 h from 5-mg pilocarpine intake. Patients with pSS and SLE were receiving antimalarial agents and a stable dose of prednisone <7.5 mg/day. Patients with RA were treated with methotrexate 10–15 mg/week. Patients with SSc were treated with iloprost, calcium channel blockers, and acetylsalicylic acid.

Collection and preparation of saliva samples

Whole saliva was collected with a very soft plastic aspirator between 2:00 PM and 4:00 PM to reduce variations in concentrations associated with circadian rhythms of secretion. Samples were collected at least 30 minutes after any food or beverage had been consumed and teeth had been cleaned. A total of 0.5 ml of saliva was collected from each subject. Immediately after collection, samples were placed in an ice bath, and 0.5 ml of an acidic solution (0.2 % trifluoroacetic acid [TFA]) was added at a 1:1 ratio (vol/vol). The solution was then centrifuged at 8000 × g for 5 minutes at 4 °C. The supernatant was removed, and the precipitate was discarded. The supernatant was immediately analyzed by high-performance liquid chromatography (HPLC) in conjunction with mass spectrometry (MS) using a spectrometer equipped with an electrospray ionization (ESI) source. HPLC-ESI-MS was performed within 30 minutes of collection of the saliva sample.

HPLC-ESI-MS analysis of salivary proteins

The HPLC-ESI-MS apparatus used was a Surveyor HPLC instrument (Thermo Fisher Scientific, Waltham, MA, USA) connected by a T splitter to a photodiode array detector and an LCQ Deca XP Plus mass spectrometer (Thermo Fisher Scientific). The chromatography column was a Vydac C8 column (Thermo Fisher Scientific) with a 5-μm particle diameter (column dimensions of 150 mm in length × 2.1-mm inner dimension). The following solutions were used for reversed-phase chromatography: Eluent A consisted of 0.056 % (vol/vol) aqueous TFA, and eluent B consisted of 0.050 % (vol/vol) TFA in acetonitrile/water 80/20 (vol/vol). The gradient applied was linear, from 0 % to 55 % of eluent B over 40 minutes, at a flow rate of 0.30 ml/minute. The T splitter addressed a flow rate of approximately 0.20 ml/minute toward the diode array detector and a flow rate of about 0.10 ml/minute toward the ESI source. The diode array detector was set at two wavelengths: 214 nm and 276 nm. Mass spectra were collected every 3 milliseconds in the positive ion mode. The MS spray voltage was 4.50 kV, and the capillary temperature was 250 °C. All common chemicals and reagents for the HPLC-MS analysis were of analytical grade and were purchased from Merck (Darmstadt, Germany) and Baker (Mallinckrodt Baker B.V., Deventer, the Netherlands). Deconvolution of the average ESI mass spectra was automatically performed by using MagTran 1.0 software (Amgen, Thousand Oaks, CA, USA) [32]. Experimental mass values obtained from the analysis were compared with theoretical values available from the Swiss-Prot [33] and EMBL [34] databases. The relative abundance of the different salivary Tβs was determined by using the extracted-ion current (XIC) strategy. The XIC procedure for each protein was based on the extraction from the total ion current profile of three mass-to-charge (m/z) values selected for each protein among the most relevant, provided that these did not overlap with the m/z values of nearly eluting proteins. Taking into account that constant analytical conditions were used for each sample, the numerical value corresponding to the integrated XIC peak area was used for the estimations of the relative abundance of peptides/proteins and for the statistical analysis. The calculated areas are all referred to a saliva volume of 17 μl. Standards of Tβ4 and Tβ10 were purchased from Bachem (Bubendorf, Switzerland), and the standard of Tβ4 sulfoxide was obtained, as previously described, by oxidation of Tβ4 [17].

Immunohistochemical analyses

Samples of minor salivary glands were obtained through an incisional biopsy taken (after inducing local anesthesia) at the endobuccal border of the lower lip from six female patients affected by SS, three with ss/SSc, three with ss/SLE, and three with ss/RA, as well as from three healthy control subjects. In patients with SS, minor salivary gland samples had an average focus score >1 according to the Chisholm-Mason scoring system. The focus score was calculated as the number of lymphocytic foci multiplied by 4-mm2 surface in at least four informative lobules, and a focus was defined as a cluster of at least 50 lymphocytes [35].

All tissue samples were fixed in 10 % formalin, routinely processed, and embedded in paraffin. Immunohistochemistry was performed on 4-μm-thick sections using a labeled streptavidin-biotin complex system (LSAB2; Dako, Glostrup, Denmark) in an autostainer (Dako Cytomation, Carpinteria, CA, USA). Briefly, paraffin sections were deparaffinized and rehydrated, and endogenous peroxidase activity was quenched by 0.3 % hydrogen peroxide in methanol (30 minutes). Heat-induced antigen retrieval was carried out by steaming unstained sections in the target retrieval solution (pH 6.1; Dako) for 30 minutes. Serial sections were then incubated with 10 % normal goat serum in PBS for 60 minutes to block nonspecific binding, followed by incubation with a polyclonal anti-Tβ4 antibody (Bachem-Peninsula Laboratories, San Carlos, CA, USA) and with a monoclonal anti-Tβ10 antibody (Bachem-Peninsula Laboratories), diluted 1:600 and 1:500, respectively, in the blocking solution. Slides were then extensively washed with PBS containing 0.01 % Triton X-100 and incubated with a secondary reagent (EnVision kit; Dako) according to the manufacturer’s instructions. Diaminobenzidine was used as a chromogen. After additional washes, color was developed using the AEC reagent (Dako), and sections were counterstained with Mayer’s hematoxylin and mounted. Sections of reactive lymph nodes with Tβ4- and Tβ10-immunoreactive histiocytes were used as a positive control. As a negative control, the same procedure was applied with minor salivary gland sections, omitting the primary antibody.

Statistical analyses

Statistical analysis was performed with SPSS version 13.0 software (SPSS, Chicago, IL, USA). Categorical and quantitative variables were described as numbers and percentages, respectively, as well as the mean ± SD. In the eight different patient subgroups considered, the analysis was performed by considering the differences either in the frequency of every single protein or in its levels. The Mann-Whitney U test and Wilcoxon’s matched-pairs signed-rank test were used to compare continuous variables. Categorical variables were analyzed using the chi-square test or Fisher’s exact test, depending on sample size restrictions. A p value ≤0.05 was considered significant.

Results

Proteomic analysis of salivary Tβ4 and Tβ10

4 was detected in the saliva of the vast majority of patients affected by SICCA (pSS + ss), with percentages ranging from 85.7 % in the subjects with ss/SSc and those with ss/RA to 88.9 % in subjects affected by pSS and to 100 % in patients with ss/SLE. Tβ4 was detected in the saliva of 90 % of healthy subjects. Salivary Tβ4 was detected at lower percentages in patients with autoimmune diseases and without ss, ranging from 28.6 % in the SLE group to 42.8 % in patients with SSc and those with RA (Tables 2 and 3).
Table 2

Thymosin β levels and frequency detection in different subgroups

 

4

10

4 sulfoxide

pSS

3.5 ± 3.1 (n = 8)a

0.2 ± 0.3 (n = 6)

1.6 ± 3.3 (n = 4)a

ss/SSc

0.7 ± 1.0 (n = 6)b

0.03 ± 0.05 (n = 3)a,b

0.2 ± 0.4 (n = 3)

ss/SLE

0.6 ± 0.4 (n = 7)b

N/A (n = 1)

N/A (n = 1)

ss/RA

1.2 ± 1.1 (n = 6)

N/A (n = 1)

N/A (n = 1)

SSc

0.3 ± 0.6 (n = 3)b

N/A (n = 0)b

N/A (n = 0)

SLE

0.1 ± 0.2 (n = 2)a,b

N/A (n = 0)b

N/A (n = 0)

RA

0.2 ± 0.4 (n = 3)

N/A (n = 0)b

N/A (n = 0)

HC

0.8 ± 0.6 (n = 9)

N/A (n = 0)b

N/A (n = 0)

Abbreviations: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy control subjects, N/A Not applicable to the comparison between levels (as continuous variable) because of too few patients with detectable thymosins in the considered group

Values are the mean ± SD protein levels in the extracted ion current area (×108). Values in parentheses are the number of subjects in whom the protein was identified

a p ≤ 0.05 vs HC either in levels of thymosin β and/or in its presence

b p ≤ 0.05 vs pSS either in thymosin β levels and/or in its presence

Table 3

Immunohistochemical and salivary detection of thymosin β in different subgroups

Group

4 IHC

4 saliva

4 sulfoxide saliva

10 saliva

10 IHC

pSS

88.9 %

44.4 %

66.7 %

+++

ss/SSc

+

85.7 %

42.9 %

42.8 %

+

ss/SLE

+

100 %

14.3 %

14.3 %

+

ss/RA

85.7 %

14.3 %

14.3 %

+++

HC

90 %

0 %

0 %

Abbreviations: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy control subjects, IHC Immunohistochemical staining, − Negative staining, + Positive staining

4 sulfoxide was found in a lower percentage of patients affected by SICCA (pSS + ss), ranging from 14.3 % in the ss/RA and ss/SLE groups to 42.9 % in the ss/SSc patients and up to 44.4 % in the pSS group. No healthy subjects showed the presence of Tβ4 sulfoxide in saliva (Tables 2 and 3).

Marked differences were observed among the different subgroups of patients affected by SICCA (pSS + ss) regarding the occurrence of Tβ10 in saliva. The percentage of salivary Tβ10 ranged from 14.3 % in the ss/SLE and ss/RA groups to 42.8 % in the patients with ss/SSc and up to 66.7 % in subjects affected by pSS.

No healthy subjects showed the presence of Tβ10 in saliva. In patients affected by SSc, RA, and SLE but without ss, both Tβ4 sulfoxide and Tβ10 were constantly absent in saliva (Tables 2 and 3).

When quantitative analyses of the salivary levels of thymosins were carried out, the highest levels of Tβ4, Tβ10, and Tβ4 sulfoxide were found in patients with pSS (3.5 ± 3.1 × 108, 0.2 ± 0.3 × 108, and 1.6 ± 3.3 × 108, respectively) (Table 2). Tβ4 levels in subjects with pSS (3.5 ± 3.1 × 108) were significantly higher than in the HC group (0.8 ± 0.6 × 108) (p < 0.05).

All patients with SS and all patients with ss were treated with a single oral dose of 5 mg of pilocarpine, and their thymosin levels were evaluated before and after treatment. No differences were found in Tβ4, Tβ10, and Tβ4 sulfoxide levels before and after the drug intake in patients with SICCA (pSS and ss).

Histology and immunohistochemistry

The histological picture of minor salivary glands in patients affected by pSS was characterized by the presence of an inflammatory infiltrate represented mainly by lymphocytes, with a focus score >1 in all cases in which histology was performed. On the contrary, no inflammatory infiltrate was detected in minor salivary glands taken from patients in the other groups.

At the time of immunohistochemistry, Tβ4 and Tβ10 were not detectable in the minor salivary glands of the healthy subjects. Marked differences were detected regarding the expression of Tβ4 and Tβ10 in patients affected by pSS, whereas the latter was characterized by high immunostaining, appearing as cytoplasmic granular deposits in acinar serous cells. On the contrary, immunoreactivity for Tβ4 was completely absent in acinar as well as ductal cells (Fig. 1). A similar immunohistochemical staining (IHC) pattern was detected in patients affected by ss/RA, with minor salivary glands being characterized by a strong, diffuse, homogeneous reactivity for Tβ10 in ductal cells and absence of any significant immunostaining for Tβ4. A different IHC pattern, characterized by immunostaining for both Tβ4 and Tβ10 in acinar cells, was observed in patients with ss/SSc or ss/SLE.
Fig. 1

Thymosin β4 (Tβ4) and Tβ10 immunostaining in patients with primary Sjögren’s syndrome (pSS) and sicca symptoms and other autoimmune diseases. a10 in patients with pSS: immunoreactive granules in acinar cells. b4 in patients with pSS: No immunoreactivity is detected in acinar and ductal cells. c10 in patients with sicca syndrome and rheumatoid arthritis (ss/RA): Strong immunostaining is observed in ductal cells. d4 in patients with ss/RA: No reactivity is observed in either acinar or in ductal cells. e4 in patients with systemic sclerosis and sicca syndrome (ss/SSc): Granular immunostaining is observed in acinar cells. f10 in patients with ss/SSc: Immunoreactivity is observed mainly in serous acinar cells

Discussion

In SS, the proteomic analysis of saliva appears to be a very useful way to assess how the autoimmune disease affects the exocrine function of salivary glands. It is an important tool for identifying biomarkers and posttranslational modifications, as well as for identifying and quantifying peptides, proteins, and neoantigens. A number of proteins have been indicated as pSS biomarkers, showing two- to threefold up- or downregulation at significantly different levels compared with healthy subjects or having an exclusive presence in SS saliva. Proteins of acinar origin (i.e., α-amylase, carbonic anhydrase VI, proline-rich proteins, prolactin-inducible protein precursor) were reduced in patients with pSS, while inflammatory phase proteins, protease inhibitors, and antimicrobial peptides (i.e., lactoferrin, β2-microglobulin, immunoglobulin κ-light chain, calgranulin B, lipocalin 1 precursor, phosphatidylethanolamine binding protein, and defensins) were increased, compared with those in healthy subjects [36].

Recently, Tβs, which are ubiquitous peptides with interesting intra- and extracellular functions, were identified in human saliva [17, 18]. Their roles in cytoskeleton rearrangement, anti-inflammatory response, stimulation of wound healing, re-epithelialization of damaged cornea, cardiac protection, and angiogenesis [912] support a possible release of Tβ in the saliva of patients with oral mucosal damage, such as in pSS, and therefore a possible involvement of these peptides in the pathogenesis of pSS.

4 is the most abundant Tβ, representing about 70–80 % of the total Tβ content, and it is a multifunctional protein that has pleotropic activities important in cell survival and repair. It is present in all cells except red blood cells, as well as in all studied body fluid (saliva, tears, blood, plasma, wound fluid) [710]. Because Tβ4 lacks a secretion signal, it is speculated that its presence in body fluids is due to damaged cells. It is localized both in the cytoplasm and in the cell nucleus. Tβ4 has been shown to promote dermal and ocular repair [19], in part because of its potent chemotactic activity. It promotes the migration of various other cells, including stem cells from the hair follicles, resulting in increased hair growth [10]; tumor cells, resulting in increased metastasis; and embryonic progenitor cells from cardiac tissue, resulting in the formation of new vessels [1113]. Tβ4 has been detected in human whole saliva and in tears by immunological techniques [18], and recent studies by our group evidenced that, in the oral cavity, a main contribution derives from crevicular fluid [17], where, as demonstrated by Reti and coworkers [20], Tβ4 plays an important role in suppressing the production of interleukin-8 following stimulation by tumor necrosis factor-α and acts on the whole saliva as an antimicrobial, anti-inflammatory, and antiapoptotic peptide on gingival fibroblasts. The ability of Tβ4 to block apoptosis and downregulate inflammatory cytokines may explain its anti-inflammatory activity. Tβ4 also increases oxidative enzymes and protects cells and tissues from oxidative damage. In different body fluids, the oxidation product of Tβ4 at the methionine-6 residue, Tβ4 sulfoxide was also detectable. Tβ4 sulfoxide is generated by monocytes in the presence of glucocorticoids, and, like Tβ4, it seems to have anti-inflammatory properties [25, 26].

4 frequently coexists with a second member of the Tβ family: Tβ10 [13]. Tβ10 concentration is usually about 20 times lower than Tβ4 in normal tissues, but the Tβ10/Tβ4 ratio seems to increase in preneoplastic and neoplastic tissues and in activated lymphocytes [13].

Whereas Tβ4 is a potent enhancer of angiogenesis, Tβ10 inhibits it, and changes in the ratio of the two peptides can exert either a positive or negative control [10]. Tβ4 can upregulate the expression of hepatocyte growth factor and downregulate the expression of platelet-derived growth factor-β receptor in a model of liver fibrosis, suggesting an antifibrotic potential of Tβ4 [36, 37].

In this study, the presence and the levels of Tβ4, Tβ4 sulfoxide, and Tβ10 were determined both in saliva by a proteomic approach and in salivary glands by immunohistochemistry. This integrated approach allowed us to compare Tβ4 and Tβ10 expression in saliva and in salivary glands of healthy subjects, patients with pSS, and patients with ss and other autoimmune diseases. Tβ4 was present in the saliva of the vast majority of patients complaining of ss symptoms and in healthy control subjects, but its levels were significantly higher in subjects affected by SS than in the other subgroups.

The high levels of Tβ4 found in the saliva of patients with SS contrasted with the absence of reactivity for the peptide in salivary glands observed by immunohistochemistry. This finding suggests that acinar cells of salivary glands constantly exposed to inflammatory damage of SS might release high amounts of Tβ4 in the saliva, where it would exert a cytoprotective effect in tissue repair and in the anti-inflammatory response, as previously shown in the damaged cornea [19]. Alternatively, the increased apoptosis of epithelial cells that characterize pSS can release the peptide, with the new and regenerating epithelial cells not producing enough peptide to be detected by IHC [38]. This is supported indirectly by the observation that Tβ10 is expressed more frequently than Tβ4 in IHC and that in fact Tβ10 is involved in apoptosis mechanisms [39].

10 and Tβ4 sulfoxide were selectively detectable in patients with SICCA (ss + pSS), as compared with none of the patients without associated ss or the healthy control subjects. Our data suggest that these two isoforms of Tβ could be salivary biomarkers of SICCA. The highest levels of Tβ4 sulfoxide and Tβ10 were found in patients with pSS. The increased levels of Tβ4 sulfoxide in pSS saliva could mirror the higher oxidative stress status of the oral cavity related to a characteristic inflammatory microenvironment due to the immunological destruction of the salivary glands typical of pSS. Indeed, the release of an increased amount of Tβ4 sulfoxide could represent a scavenger mechanism able to reduce the negative effects of oxidative stress on salivary proteins and enzymes, along with a cytoprotective effect, in both forms.

10 has a similar expression pattern of Tβ4 sulfoxide in pSS and ss saliva, and its presence may be due to a passive release from damaged cells, such as Tβ4. The increased amount of Tβ10 in pSS saliva could be related to the activated lymphocytes present in salivary gland infiltrates.

It has been shown that thymosins prevent scarring and fibrosis in many animal models of human pathologies through their potent regenerative and antifibrotic effect in reducing inflammation and in modulating oxidative damage. In this scenario, our data suggest a role of thymosins in pSS and in patients with ss related to other autoimmune diseases, supporting a rationale for expecting thymosins’ therapeutic effect in clinical practice in patients with ss symptoms, as well as what has already been reported in lung damage [40, 41], eye injury [19], and wound healing of the palatal mucosa [42].

Conclusions

Proteomic analysis of the expression of Tβ4, Tβ4 sulfoxide, and Tβ10 mirrors the different oral microenvironment of patients with pSS and with autoimmune diseases who complain of ss. Thymosins may potentially be used as biomarkers in patients with pSS and patients with ss, and IHC analysis helped us to hypothesize their possible role. Functional studies at the epithelial cell level are necessary to further elucidate their role.

Abbreviations

ANA: 

Antinuclear autoantibodies

ENA: 

Extractable nuclear antigen autoantibodies

ESI: 

Electrospray ionization

HC: 

Healthy control subjects

HPLC: 

High-performance liquid chromatography

IHC: 

Immunohistochemical

m/z

Mass-to-charge ratio

MS: 

Mass spectrometry

N/A: 

Not applicable

pSS: 

Primary Sjögren’s syndrome

RA: 

Rheumatoid arthritis

RF: 

Rheumatoid factor

SICCA: 

Primary Sjögren’s syndrome and sicca syndrome

SLE: 

Systemic lupus erythematosus

ss: 

Sicca syndrome

SS: 

Sjögren’s syndrome

SSc: 

Systemic sclerosis

TFA: 

Trifluoroacetic acid

Tβ: 

Thymosin β

UWS: 

Unstimulated whole saliva

XIC: 

Extracted-ion current

Declarations

Acknowledgements

None.

Funding

The study was supported by the ASRALES Foundation; the Associazione Nazionale Italiana Malati Sindrome di Sjögren (A.N.I.Ma.S.S.); the Nando Peretti Foundation; the University of Cagliari; the Italian Ministry of Education, Universities and Research (MIUR); the Italian National Research Council (CNR); and Regione Sardegna.

Authors’ contributions

SB conceived of the study; participated in study design as well as data acquisition, analysis, and interpretation; performed statistical analysis; and helped to prepare the manuscript. GP conceived of the study; participated in study design as well as data acquisition, analysis and interpretation; and was involved in manuscript preparation. FI participated in study design and data acquisition, performed proteomic analysis, helped with interpretation of the results, and revised the manuscript. BT participated in acquisition of data and interpretation of the results, performed statistical analysis, and revised the manuscript. IM conceived of the study, helped with data acquisition, performed proteomic analysis, participated in interpretation of the results, and revised the manuscript. GFa conceived of the study, performed the histological analysis, helped with interpretation of the results, and revised the manuscript. MC conceived of the study design, helped with interpretation of the results, and revised the manuscript. GFe conceived of the study, participated in study design, helped with analysis and interpretation of data, and contributed to manuscript preparation. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli
(2)
Institute of Chemistry and Clinical Biochemistry, Catholic University
(3)
Department of Life and Environmental Sciences, University of Cagliari
(4)
Department of Surgery, Section of Pathology, University of Cagliari
(5)
Institute of Rheumatology and Affine Sciences, Universita’ Cattolica del Sacro Cuore, Presidio Columbus

References

  1. Fox RI. Sjögren’s syndrome. Lancet. 2005;366(9482):321–31.View ArticlePubMedGoogle Scholar
  2. Hu S, Loo JA, Wong TS. Human saliva proteome analysis. Ann N Y Acad Sci. 2007;1098:323–9.View ArticlePubMedGoogle Scholar
  3. Baldini C, Giusti L, Bazzichi L, Lucacchini A, Bombardieri S. Proteomic analysis of the saliva: a clue for understanding primary from secondary Sjögren’s syndrome? Autoimmun Rev. 2008;7(3):185–91.View ArticlePubMedGoogle Scholar
  4. Fleissig Y, Deutsh O, Reichenberg E, Redlich M, Zaks B, Palmon A, et al. Different proteomic protein patterns in saliva of Sjögren’s syndrome patients. Oral Dis. 2009;15(1):61–8.View ArticlePubMedGoogle Scholar
  5. Ferraccioli G, De Santis M, Peluso G, Inzitari R, Fanali C, Bosello SL, et al. Proteomic approaches to Sjögren’s syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev. 2010;9(9):622–6.View ArticlePubMedGoogle Scholar
  6. Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56(7):2216–22.View ArticlePubMedGoogle Scholar
  7. Hannappel E. β-Thymosins. Ann N Y Acad Sci. 2007;1112:21–37.View ArticlePubMedGoogle Scholar
  8. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205–20.View ArticlePubMedGoogle Scholar
  9. Mannherz HG, Hannappel E. The β-thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motil Cytoskeleton. 2009;66(10):839–51.View ArticlePubMedGoogle Scholar
  10. Philp D, Goldstein AL, Kleinman HK. Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113–5.View ArticlePubMedGoogle Scholar
  11. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–72.View ArticlePubMedGoogle Scholar
  12. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–82.View ArticlePubMedGoogle Scholar
  13. Hall AK. Differential expression of thymosin genes in human tumors and in developing human kidney. Int J Cancer. 1991;48(5):672–7.View ArticlePubMedGoogle Scholar
  14. Sun W, Kim H. Neurotrophic roles of the β-thymosins in the development and regeneration of the nervous system. Ann N Y Acad Sci. 2007;1112:210–8.View ArticlePubMedGoogle Scholar
  15. Nemolato S, Cabras T, Fanari MU, Cau F, Fanni D, Gerosa C, et al. Immunoreactivity of Thymosin β4 in human foetal and adult genitourinary tract. Eur J Histochem. 2010;54(4):e43.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Naylor PH, McClure JE, Spangelo BL, Low TL, Goldstein AL. Immunochemical studies on thymosin: radioimmunoassay of thymosin β4. Immunopharmacology. 1984;7(1):9–16.View ArticlePubMedGoogle Scholar
  17. Inzitari R, Cabras T, Pisano E, Fanali C, Manconi B, Scarano E, et al. HPLC-ESI-MS analysis of oral human fluid reveals that gingival crevicular fluids the main source of oral thymosins β4 and β10. J Sep Sci. 2009;32(1):57–63.View ArticlePubMedGoogle Scholar
  18. Badamchian M, Damavandy AA, Damavandy H, Wadhwa SD, Katz B, Goldstein AL. Identification and quantification of thymosin β4 in human saliva and tears. Ann N Y Acad Sci. 2007;1112:458–65.View ArticlePubMedGoogle Scholar
  19. Sosne G, Chan CC, Thai K, Kennedy M, Szliter EA, Hazlett LD, et al. Thymosin β4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72(5):605–8.View ArticlePubMedGoogle Scholar
  20. Reti R, Kwon E, Qiu P, Wheater M, Sosne G. Thymosin β4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):424–30.View ArticlePubMedGoogle Scholar
  21. Nemolato S, Messana I, Cabras T, Manconi B, Inzitari R, Fanali C, et al. Thymosin β4 and β10 levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development. PLoS One. 2009;4(4):e5109.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Santelli G, Califano D, Chiappetta G, Vento MT, Bartoli PC, Zullo F, et al. Thymosin β-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol. 1999;155(3):799–804.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Hall AK, Hempstead J, Morgan JI. Thymosin β10 levels in developing human brain and its regulation by retinoic acid in the HTB-10 neuroblastoma. Brain Res Mol Brain Res. 1990;8(2):129–35.View ArticlePubMedGoogle Scholar
  24. Shiotsuka M, Wada H, Kiyoshima T, Nagata K, Fujiwara H, Kihara M, et al. The expression and function of thymosin β10 in tooth germ development. Int J Dev Biol. 2013;57(11-12):873–83.View ArticlePubMedGoogle Scholar
  25. Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, et al. Thymosin β4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1995;5(12):1424–7.Google Scholar
  26. De Santis M, Inzitari R, Bosello SL, Peluso G, Fanali C, Iavarone F, et al. β-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. Respir Res. 2011;12:22.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken). 2012;64(4):475–87.View ArticleGoogle Scholar
  29. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581–90.View ArticleGoogle Scholar
  30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.View ArticlePubMedGoogle Scholar
  31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.View ArticlePubMedGoogle Scholar
  32. Zhang Z, Marshall AG. A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. J Am Soc Mass Spectrom. 1998;9(3):225–33.View ArticlePubMedGoogle Scholar
  33. Swiss Institute of Bioinformatics (SIB). ExPASy Bioinformatics Resource Portal [Swiss-Prot]. http://www.expasy.org/tools.
  34. European Molecular Biology Laboratory (EMBL) database. http://www.embl-heidelberg.de.
  35. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol. 2002;29(5):938–44.PubMedGoogle Scholar
  36. Barnaeva E, Nadezhda A, Hannappel E, Sjogren MH, Rojkind M. Thymosin β4 upregulates the expression of hepatocyte growth factor and downregulates the expression of PDGF-β receptor in human hepatic stellate cells. Ann N Y Acad Sci. 2007;1112:154–60.View ArticlePubMedGoogle Scholar
  37. Oh IS, So SS, Jahng KY, Kim HG. Hepatocyte growth factor upregulates thymosin beta4 in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;296(2):401–5.View ArticlePubMedGoogle Scholar
  38. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjögren’s syndrome (SS). Clin Exp Immunol. 1998;114(3):485–90.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Hall AK. Thymosin β-10 accelerates apoptosis. Cell Mol Biol Res. 1995;41(3):167–80.PubMedGoogle Scholar
  40. Conte E, Genovese T, Gili E, Esposito E, Iemmolo M, Fruciano M, et al. Protective effects of thymosin β4 in a mouse model of lung fibrosis. Ann N Y Acad Sci. 2012;1269:69–73.View ArticlePubMedGoogle Scholar
  41. Conte E, Fagone E, Gili E, Fruciano M, Iemmolo M, Pistorio MP, et al. Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. Oncotarget. 2016;7(23):33841–54. doi:10.18632/oncotarget.8409.Google Scholar
  42. Zhu T, Park HC, Son KM, Kwon JH, Park JC, Yang HC. Effects of thymosin β4 on wound healing of rat palatal mucosa. Int J Mol Med. 2014;34(3):816–21.PubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement